Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Halilbasic Emina |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2025
Originalarbeit (Zeitschrift)
** Zhu, C; Boucheron, N; Al-Rubaye, O; Chung, BK; Thorbjørnsen, LW; Köcher, T; Schuster, M; Claudel, T; Halilbasic, E; Kunczer, V; Muscate, F; Cavanagh, LL; Waltenberger, D; Lercher, A; Ohradanova-Repic, A; Schatzlmaier, P; Stojakovic, T; Scharnagl, H; Bergthaler, A; Stockinger, H; Huber, S; Bock, C; Kenner, L; Karlsen, TH; Ellmeier, W; Trauner, M
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting TH17 pathogenicity and transdifferentiation.
Gut. 2025;
Doi: 10.1136/gutjnl-2024-333297
Web of Science
PubMed
FullText
FullText_MUG
2024
Originalarbeit (Zeitschrift)
** Zecher, BF; Ellinghaus, D; Schloer, S; Niehrs, A; Padoan, B; Baumdick, ME; Yuki, Y; Martin, MP; Glow, D; Schröder-Schwarz, J; Niersch, J; Brias, S; Müller, LM; Habermann, R; Kretschmer, P; Früh, T; Dänekas, J; Wehmeyer, MH; Poch, T; Sebode, M; Ellinghaus, E; Degenhardt, F; Körner, C; Hoelzemer, A; Fehse, B; Oldhafer, KJ; Schumacher, U; Sauter, G; Carrington, M; Franke, A; Bunders, MJ; Schramm, C; Altfeld, M, , International, PSC, Study, Group, (IPSCSG)
HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
Gut. 2024; 73(2): 325-337.
Doi: 10.1136/gutjnl-2023-329524
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Trauner, M; Halilbasic, E; Tatscher, E; Fickert, P
[Primary sclerosing cholangitis-Diagnosis and treatment 2024].
INNERE MED. 2024; 65(4): 347-356.
Doi: 10.1007/s00108-024-01697-0
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2023
Abstract (Zeitschrift)
** Trauner, M; Fickert, P; Trivedi, P; Denk, G; Färkkilä, M; Dill, M; Villadsen, GE; Berg, C; Jorgensen, KK; Vetter, M; Müller, T; Müllhaupt, B; Schramm, C; Strassburg, C; Bantel, H; Böttler, T; Beuers, U; Louvet, A; Halilbasic, E; Stiess, M; Proels, M; Manns, MP
Norucholic acid for the treatment of primary sclerosing cholangitis: baseline data from a phase III trial
J HEPATOL. Abstracts. 2023; 78(S1):S403-S403.-EASL Congress 2023; JUN 21-24, 2023; Vienna, AUSTRIA.
[Oral Communication]
Web of Science
2022
Originalarbeit (Zeitschrift)
** Fuchs, CD; Radun, R; Dixon, ED; Mlitz, V; Timelthaler, G; Halilbasic, E; Herac, M; Jonker, JW; Ronda, OAHO; Tardelli, M; Haemmerle, G; Zimmermann, R; Scharnagl, H; Stojakovic, T; Verkade, HJ; Trauner, M
Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice.
Hepatology. 2022; 75(1):125-139
Doi: 10.1002/hep.32112
Web of Science
PubMed
FullText
FullText_MUG
2021
Originalarbeit (Zeitschrift)
** Traussnigg, S; Halilbasic, E; Hofer, H; Munda, P; Stojakovic, T; Fauler, G; Kashofer, K; Krssak, M; Wolzt, M; Trauner, M
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.
Wien Klin Wochenschr. 2021; 133(9-10):441-451
Doi: 10.1007/s00508-020-01735-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zhu, C; Boucheron, N; Müller, AC; Májek, P; Claudel, T; Halilbasic, E; Baazim, H; Lercher, A; Viczenczova, C; Hainberger, D; Preglej, T; Sandner, L; Alteneder, M; Gülich, AF; Khan, M; Hamminger, P; Remetic, J; Ohradanova-Repic, A; Schatzlmaier, P; Donner, C; Fuchs, CD; Stojakovic, T; Scharnagl, H; Sakaguchi, S; Weichhart, T; Bergthaler, A; Stockinger, H; Ellmeier, W; Trauner, M
24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation.
J Hepatol. 2021; 75(5):1164-1176
Doi: 10.1016/j.jhep.2021.06.036
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Originalarbeit (Zeitschrift)
** Staufer, K; Halilbasic, E; Spindelboeck, W; Eilenberg, M; Prager, G; Stadlbauer, V; Posch, A; Munda, P; Marculescu, R; Obermayer-Pietsch, B; Stift, J; Lackner, C; Trauner, M; Stauber, RE
Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease
UNITED EUR GASTROENT. 2019; UNSP 2050640619865133
Doi: 10.1177/2050640619865133
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Traussnigg, S; Schattenberg, JM; Demir, M; Wiegand, J; Geier, A; Teuber, G; Hofmann, WP; Kremer, AE; Spreda, F; Kluwe, J; Petersen, J; Boettler, T; Rainer, F; Halilbasic, E; Greinwald, R; Pröls, M; Manns, MP; Fickert, P; Trauner, M; Austrian/German NAFLD-norUDCA study group
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Lancet Gastroenterol Hepatol. 2019; 4(10):781-793
Doi: 10.1016/S2468-1253(19)30184-0
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Menz, M; Hinterleitner, L; Konigshofer, P; Halilbasic, E; Kunczer, V; Stojakovic, T; Reiberger, T; Fuchs, C; Trauner, M
Glucagon like peptide-2 treatment improves liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis
J HEPATOL. 2019; 70: E167-E168.
Doi: 10.1016/S0618-8278(19)30301-9
[Poster]
Web of Science
FullText
FullText_MUG
** Zhu, C; Boucheron, N; Muller, A; Majek, P; Fuchs, C; Baazim, H; Lercher, A; Halilbasic, E; Gulich, A; Sakaguchi, S; Sandner, L; Stojakovic, T; Scharnagl, H; Bergthaler, A; Ellmeier, W; Trauner, M
24-nor-ursodeoxycholic acid ameliorates inflammation by reshaping mTOR proteome and immunometabolism sensing programs in CD8 T cells
EUR J IMMUNOL. 2019; 49: 1282-1282.-17th International Congress of Immunology (IUIS); OCT 19-23, 2019; Beijing, PEOPLES R CHINA.
[Poster]
Web of Science
** Zhu, C; Boucheron, N; Muller, A; Majek, P; Fuchs, CD; Baazim, H; Halilbasic, E; Stojakovic, T; Bergthaler, A; Ellmeier, W; Trauner, M
24-nor-ursodeoxycholic acid ameliorates inflammation by reshaping mTOR proteome and immunometabolism sensing programs in CD8 T-cells
J HEPATOL. 2019; 70(1): E9-E10.
Doi: 10.1016/S0618-8278(19)30016-7
[Poster]
Web of Science
FullText
FullText_MUG
2018
Originalarbeit (Zeitschrift)
** Fuchs, CD; Paumgartner, G; Mlitz, V; Kunczer, V; Halilbasic, E; Leditznig, N; Wahlström, A; Ståhlman, M; Thüringer, A; Kashofer, K; Stojakovic, T; Marschall, HU; Trauner, M
Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.
Gut. 2018; 67(9):1683-1691
Doi: 10.1136/gutjnl-2017-314553
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Menz, M; Hinterleitner, L; Konigshofer, P; Halilbasic, E; Kunczer, V; Stojakovic, T; Reiberger, T; Fuchs, CD; Trauner, MH
Glucagon like Peptide (GLP)-2 Treatment Improves Liver and Bile Duct Injury in the Mdr2-/- Mouse Model of Sclerosing Cholangitis
HEPATOLOGY. . 2018; 68: 831A-831A.-Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting; NOV 09-13, 2018; San Francisco, CA.
[Poster]
Web of Science
2017
Originalarbeit (Zeitschrift)
** Fickert, P; Hirschfield, GM; Denk, G; Marschall, HU; Altorjay, I; Färkkilä, M; Schramm, C; Spengler, U; Chapman, R; Bergquist, A; Schrumpf, E; Nevens, F; Trivedi, P; Reiter, FP; Tornai, I; Halilbasic, E; Greinwald, R; Pröls, M; Manns, MP; Trauner, M; European PSC norUDCA Study Group
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
J Hepatol. 2017; 67(3):549-558
Doi: 10.1016/j.jhep.2017.05.009
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Fuchs, CD; Paumgartner, G; Halilbasic, E; Leditznig, N; Wahlstrom, A; Stahlman, M; Stojakovic, T; Marschall, HU; Trauner, M
Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(-/-) mice by modulating fecal bile acid composition and signaling
J HEPATOL. .. 2017; 66(1):S364-S364.-International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver; APR 19-23, 2017; Amsterdam, NETHERLANDS.
Doi: 10.1016/S0168-8278(17)31068-1
[Poster]
Web of Science
FullText
FullText_MUG
** Traussnigg, S; Schattenberg, JM; Demir, M; Wiegand, J; Geier, A; Teuber, G; Hofmann, WP; Kremer, AE; Spreda, F; Kluwe, J; Petersen, J; Boettler, T; Halilbasic, E; Greinwald, R; Proels, M; Manns, MP; Fickert, P; Trauner, MH
norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study
HEPATOLOGY. 2017; 66: 106A-107A.-68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting; OCT 20-24, 2017; Washington, DC.
[Oral Communication]
Web of Science
2016
Originalarbeit (Zeitschrift)
** Baghdasaryan, A; Fuchs, CD; Österreicher, CH; Lemberger, UJ; Halilbasic, E; Påhlman, I; Graffner, H; Krones, E; Fickert, P; Wahlström, A; Ståhlman, M; Paumgartner, G; Marschall, HU; Trauner, M
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
J Hepatol. 2016; 64(3):674-681
Doi: 10.1016/j.jhep.2015.10.024
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Trauner, M; Fickert, P; Hirschfield, G; Reiter, F; Altorjay, I; Marschall, U; Farkkila, M; Schramm, C; Spengler, U; Chapman, R; Bergquist, A; Schrumpf, E; Nevens, F; Halilbasic, E; Greinwald, R; Proels, M; Manns, MP;
NORURSODEOXYCHOLIC ACID IMPROVES CHOLESTASIS IN PRIMARY SCLEROSING CHOLANGITIS: RESULTS OF A PHASE II DOSE FINDING STUDY.
J HEPATOL. 2016; 64: S208-S209.-EASL International Liver Congress; APR 13-17, 2016; Barcelona, SPAIN.
Doi: 10.1016/S0168-8278(16)00171-9
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Trauner, MH; Fickert, P; Hirschfield, G; Denk, G; Altorjay, I; Marschall, HU; Farkkila, MA; Schramm, C; Spengler, U; Chapman, RW; Bergquist, A; Schrumpf, E; Nevens, F; Halilbasic, E; Greinwald, R; Prols, M; Manns, MP
norUrsodeoxycholic acid (norUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response
HEPATOLOGY. 2016; 63(1 SUPP):111A-111A.-67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD); NOV 11-15, 2016; Boston, MA.
[Oral Communication]
Web of Science
2015
Originalarbeit (Zeitschrift)
** Chmelík, M; Valkovič, L; Wolf, P; Bogner, W; Gajdošík, M; Halilbasic, E; Gruber, S; Trauner, M; Krebs, M; Trattnig, S; Krššák, M
Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver.
Eur Radiol. 2015; 25(7):2059-2066
Doi: 10.1007/s00330-014-3578-y
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Trauner, M; Halilbasic, E; Claudel, T; Steinacher, D; Fuchs, C; Moustafa, T; Pollheimer, M; Krones, E; Kienbacher, C; Traussnigg, S; Kazemi-Shirazi, L; Munda, P; Hofer, H; Fickert, P; Paumgartner, G
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Dig Dis. 2015; 33(3):433-439
Doi: 10.1159/000371904
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Fuchs, CD; Claudel, T; Halilbasic, E; Jha, P; Spindelboeck, W; Stojakovic, T; Trauner, M
ROLE OF FXR CONTROLLED Chop IN MEDIATING BILE ACID EFFECTS IN NAFLD.
J HEPATOL. 2015; 62(S2):S689-S689.-50th Annual Meeting of the European Association for the Study of the Liver (EASL); APR 22-26, 2015; Vienna, AUSTRIA.
[Poster]
Web of Science
2014
Originalarbeit (Zeitschrift)
** García-Rodríguez, JL; Barbier-Torres, L; Fernández-Álvarez, S; Gutiérrez-de Juan, V; Monte, MJ; Halilbasic, E; Herranz, D; Álvarez, L; Aspichueta, P; Marín, JJ; Trauner, M; Mato, JM; Serrano, M; Beraza, N; Martínez-Chantar, ML
SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.
Hepatology. 2014; 59(5):1972-1983
Doi: 10.1002/hep.26971
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Jha, P; Claudel, T; Baghdasaryan, A; Mueller, M; Halilbasic, E; Das, SK; Lass, A; Zimmermann, R; Zechner, R; Hoefler, G; Trauner, M
Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia.
Hepatology. 2014; 59(3):858-869
Doi: 10.1002/hep.26732
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Cuperus, FJ; Claudel, T; Gautherot, J; Halilbasic, E; Trauner, M
The role of canalicular ABC transporters in cholestasis.
Drug Metab Dispos. 2014; 42(4):546-560
Doi: 10.1124/dmd.113.056358
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Cuperus, FJ; Halilbasic, E; Trauner, M
Fibrate treatment for primary biliary cirrhosis.
Curr Opin Gastroenterol. 2014; 30(3): 279-286.
Doi: 10.1097/MOG.0000000000000056
Web of Science
PubMed
FullText
FullText_MUG
** Staufer, K; Halilbasic, E; Trauner, M; Kazemi-Shirazi, L
Cystic fibrosis related liver disease--another black box in hepatology.
Int J Mol Sci. 2014; 15(8):13529-13549
Doi: 10.3390/ijms150813529
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Trauner, M; Halilbasic, E; Kazemi-Shirazi, L; Kienbacher, C; Staufer, K; Traussnigg, S; Hofer, H
Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Dig Dis. 2014; 32(5):631-636
Doi: 10.1159/000360517
Web of Science
PubMed
FullText
FullText_MUG
2013
Originalarbeit (Zeitschrift)
** Fickert, P; Krones, E; Pollheimer, MJ; Thueringer, A; Moustafa, T; Silbert, D; Halilbasic, E; Yang, M; Jaeschke, H; Stokman, G; Wells, RG; Eller, K; Rosenkranz, AR; Eggertsen, G; Wagner, CA; Langner, C; Denk, H; Trauner, M
Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.
Hepatology. 2013; 58(6):2056-2069
Doi: 10.1002/hep.26599
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Fickert, P; Pollheimer, MJ; Silbert, D; Moustafa, T; Halilbasic, E; Krones, E; Durchschein, F; Thüringer, A; Zollner, G; Denk, H; Trauner, M
Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
J Hepatol. 2013; 58(6):1201-1208
Doi: 10.1016/j.jhep.2013.01.026
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Halilbasic, E; Baghdasaryan, A; Trauner, M
Nuclear receptors as drug targets in cholestatic liver diseases.
Clin Liver Dis. 2013; 17(2):161-189
Doi: 10.1016/j.cld.2012.12.001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Fuchs, CD; Claudel, T; Halilbasic, E; Jha, P; Spindelboeck, W; Stojakovic, T; Trauner, M
FXR controlled CHOP as novel key player in NAFLD progression.
HEPATOLOGY. 2013; 58(S1):542A-542A.-64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); NOV 1-5, 2013; Washington, DC, USA.
[Poster]
Web of Science
** Fuchs, CD; Claudel, T; Halilbasic, E; Stojakovic, T; Trauner, M
INTRAHEPATIC CHANGES IN BILE ACID COMPOSITION PROTECTS BSEP (ABCB11) KO MICE FROM HEPATIC INFLAMMATION IN METHIONINE CHOLINE DEFICIENT DIET INDUCED NASH.
J HEPATOL. 2013; 58(S1):S32-S32.-48th Annual Meeting of the European Association for the Study of the Liver (EASL); APR 24-28, 2013; Amsterdam, THE NETHERLANDS.
Doi: 10.1016/S0168-8278(13)60072-0
[Oral Communication]
Web of Science
FullText
FullText_MUG
2012
Originalarbeit (Zeitschrift)
** Fuchs, CD; Claudel, T; Kumari, P; Haemmerle, G; Pollheimer, MJ; Stojakovic, T; Scharnagl, H; Halilbasic, E; Gumhold, J; Silbert, D; Koefeler, H; Trauner, M
Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice.
Hepatology. 2012; 56(1):270-280
Doi: 10.1002/hep.25601
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Modica, S; Petruzzelli, M; Bellafante, E; Murzilli, S; Salvatore, L; Celli, N; Di Tullio, G; Palasciano, G; Moustafa, T; Halilbasic, E; Trauner, M; Moschetta, A
Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Gastroenterology. 2012; 142(2):355-65.e1-355-65.e4
Doi: 10.1053/j.gastro.2011.10.028
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Trauner, M; Halilbasic, E; Baghdasaryan, A; Moustafa, T; Krones, E; Fickert, P; Hofer, H; Penner, E
Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment.
Dig Dis. 2012; 30 Suppl 1(6):39-47
Doi: 10.1159/000341123
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Fuchs, C; Claudel, T; Kumari, P; Stojakovic, T; Halilbasic, E; Spindelboeck, W; Gonzalez, F; Trauner, M
FXR IS A KEY PLAYER IN NAFLD DEVELOPMENT BY CONTROLLING CHOP EXPRESSION.
J HEPATOL. 2012; 56(S2):S490-S490.-47th Annual Meeting of the European Association for the Study of the Liver (EASL); APR 18-22, 2012; Barcelona, SPAIN.
Doi: 10.1016/S0168-8278(12)61248-3
[Poster]
Web of Science
FullText
FullText_MUG
** Halilbasic, E; Claudel, T; Bachhofner, N; Kapusta, C; Fickert, P; Trauner, M
Norursodeoxycholic Acid Counteracts Hepatic Acute Phase Response via Modulation of NF kappa B Signaling
HEPATOLOGY. 2012; 56: 539A-540A.-63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD); NOV 09-13, 2012; Boston, MA.
Web of Science
2011
Übersichtsarbeit
** Pollheimer, MJ; Halilbasic, E; Fickert, P; Trauner, M
Pathogenesis of primary sclerosing cholangitis.
Best Pract Res Clin Gastroenterol. 2011; 25(6):727-739
Doi: 10.1016/j.bpg.2011.10.009
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Trauner, M; Baghdasaryan, A; Claudel, T; Fickert, P; Halilbasic, E; Moustafa, T; Zollner, G
Targeting nuclear bile acid receptors for liver disease.
Dig Dis. 2011; 29(1):98-102
Doi: 10.1159/000324141
Web of Science
PubMed
FullText
FullText_MUG
** Trauner, M; Halilbasic, E
Nuclear receptors as new perspective for the management of liver diseases.
Gastroenterology. 2011; 140(4):1120-1125.e1-1120-1125.12
Doi: 10.1053/j.gastro.2011.02.044
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Fickert, P; Silbert, D; Moustafa, T; Halilbasic, E; Krones, E; Durchschein, F; Thueringer, A; Pollheimer, MJ; Zollner, G; Denk, H; Trauner, M
DIFFERENTIAL EFFECTS OF NORUDCA AND UDCA IN OBSTRUCTIVE CHOLESTASIS IN MICE
HEPATOLOGY. 2011; 54: 775A-775A.-62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD); NOV 04-08, 2011; San Francisco, CA.
[Poster]
Web of Science
** Fuchs, CD; Claudel, T; Kumari, P; Stojakovic, T; Haemmerle, G; Halilbasic, E; Gumhold, J; Silbert, D; Koefeler, H; Zechner, R; Trauner, M
ATGL (PNPLA2) KNOCKOUT MICE ARE PROTECTED FROM HEPATIC ER-STRESS VIA OLEIC ACID ACCUMULATION.
J HEPATOL. 2011; 54: S41-S42.-46th Annual Meeting of the European Association for the Study of the Liver (EASL); MAR 30-APR 3, 2011; Berlin, GERMANY.
Doi: 10.1016/S0168-8278(11)60095-0
[Poster]
Web of Science
FullText
FullText_MUG
2010
Übersichtsarbeit
** Trauner, M; Fickert, P; Baghdasaryan, A; Claudel, T; Halilbasic, E; Moustafa, T; Wagner, M; Zollner, G
New insights into autoimmune cholangitis through animal models.
Dig Dis. 2010; 28(1):99-104
Doi: 10.1159/000282072
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Abstract (Zeitschrift)
** Fuchs, CD; Moustafa, T; Haemmerle, G; Halilbasic, E; Gumhold, J; Silbert, D; Fickert, P; Zechner, R; Trauner, M
ADIPOSE TRIGLYCERIDE LIPASE (ATGL) IS A NOVEL MODULATOR OF HEPATIC ER-STRESS
J HEPATOL. 2010; 52: S305-S305.-45th Annual Meeting of the European Association for the Study of the Liver; APR 14 - 18,2010; Vienna, AUSTRIA.
Doi: 10.1016/S0168-8278(10)60787-8
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Halilbasic, E; Claudel, T; Gumhold, J; Halsegger, S; Silbert, D; Fickert, P; Trauner, M
PREGNANCY RESOLVES LIVER FIBROSIS AND IMPROVES SCLEROSING CHOLANGITIS IN MDR2 (ABCB4) -/- MICE VIA DIRECT ANTI-INFLAMMATORY EFFECTS OF SEX HORMONES
J HEPATOL. 2010; 52: S24-S24.-45th Annual Meeting of the European Association for the Study of the Liver; APR 14 - 18,2010; Vienna, AUSTRIA.
Doi: 10.1016/S0168-8278(10)60052-9
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Krones, E; Halilbasic, E; Grisold, A; Krause, R; Trauner, M; Fickert, P; Zollner, G
Acute hepatitis species as a result of contamination of a food supplement with Cytotoxin-producing Bacillus species.
WIEN KLIN WOCHENSCHR. 2010; 122(17-18):A10-A11.
[Poster]
Web of Science
2009
Originalarbeit (Zeitschrift)
** Fickert, P; Fuchsbichler, A; Moustafa, T; Wagner, M; Zollner, G; Halilbasic, E; Stöger, U; Arrese, M; Pizarro, M; Solís, N; Carrasco, G; Caligiuri, A; Sombetzki, M; Reisinger, E; Tsybrovskyy, O; Zatloukal, K; Denk, H; Jaeschke, H; Pinzani, M; Trauner, M
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.
Am J Pathol. 2009; 175(6):2392-2405
Doi: 10.2353/ajpath.2009.090114
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Halilbasic, E; Fiorotto, R; Fickert, P; Marschall, HU; Moustafa, T; Spirli, C; Fuchsbichler, A; Gumhold, J; Silbert, D; Zatloukal, K; Langner, C; Maitra, U; Denk, H; Hofmann, AF; Strazzabosco, M; Trauner, M
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Hepatology. 2009; 49(6):1972-1981
Doi: 10.1002/hep.22891
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Pressetext
Google Scholar
Originalarbeit (Konferenzband)
** Halilbasic, E; Fickert, P; Fiorotto, R; Marschall, HU; Moustafa, T; Fuchsbichler, A; Gumhold, J; Silbert, D; Langner, C; Maitra, U; Denk, H; Strazzabosco, M; Trauner, M
Side-chain modification as critical determinant of the therapeutic properties of 24-norursodeoxycholic acid in Mdr2 (Abcb4) knockout mice
FALK SYMP. 2009; 165: 157-162.
[Oral Communication]
Web of Science
** Trauner, M; Fickert, P; Moustafa, T; Fuchsbichler, A; Claudel, T; Halilbasic, E; Kratky, D; Denk, H
Potential role of ursodeoxycholic acid and its side-chain modified derivatives in the treatment of non-alcoholic fatty liver disease and associated atherosclerosis
FALK SYMP. 2009; 165: 151-156.
[Oral Communication]
Web of Science
2008
Originalarbeit (Zeitschrift)
** Baghdasaryan, A; Fickert, P; Fuchsbichler, A; Silbert, D; Gumhold, J; Hörl, G; Langner, C; Moustafa, T; Halilbasic, E; Claudel, T; Trauner, M
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice.
Liver Int. 2008; 28(7):948-958
Doi: 10.1111/j.1478-3231.2008.01758.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Übersichtsarbeit
** Trauner, M; Fickert, P; Halilbasic, E; Moustafa, T
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Wien Med Wochenschr. 2008; 158(19-20):542-548
Doi: 10.1007/s10354-008-0592-1
PubMed
FullText
FullText_MUG
Google Scholar
Abstract (Zeitschrift)
** Fickert, P; Moustafa, T; Fuchsbichler, A; Claudel, T; Halilbasic, E; Zatloukal, K; Denk, H; Trauner, M
Differential effects of nor UDCA and UDCA in the treatment of fatty liver and arteriosclerosis in western chow-fed ApoE knock out mice
J HEPATOL. 2008; 48: S42-S42.-Annual Meeting, EASL; April 2008; Milann, Italy.
Doi: 10.1016/S0168-8278(08)60100-2
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Moustafa, T; Fickert, P; Silbert, D; Gumhold, J; Halilbasic, E; Trauner, MH
LOSS OF FXR ATTENUATES SCLEROSING CHOLANGITIS AND BILIARY FIBROSIS IN MDR2(-/-) AND FXR(-/-) DOUBLE KNOCKOUT MICE
HEPATOLOGY. 2008; 48(4):777--59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases; OCT 31-NOV 04, 2008; San Francisco, CA.
[Poster]
Web of Science
** Moustafa, T; Halilbasic, E; Fickert, P; Fuchsbichler, A; Gumhold, J; Silbert, D; Denk, H; Trauner, M
Side chain modified bile acids modulate endoplasmic reticulum stress in Mdr2(-/-) mice in vivo and bile duct epithelial cells in vitro
J HEPATOL. 2008; 48: S54-S55.-EASL Annula Meeting; April 2008; Milan Italy.
Doi: 10.1016/S0168-8278(08)60127-0
[Oral Communication]
Web of Science
FullText
FullText_MUG
2007
Abstract (Zeitschrift)
** Halilbasic, E; Fickert, P; Fuchbichler, A; Langner, C; Gumhold, J; Silbert, D; Maitra, U; Zatloukal, K; Denk, H; Trauner, M
Taurine-conjugation critically determines the therapeutic effectiveness of 24-nor-ursodeoxycholic acid (norUDCA) in the treatment of sclerosing cholangitis in Mdr2 (ABCB4) knockout mice
J HEPATOL. 2007; 46: S51-S51.-EASL; April 11-15, 2007;
Doi: 10.1016/S0168-8278(07)61714-0
[Oral Communication]
Web of Science
FullText
FullText_MUG
2006
Originalarbeit (Zeitschrift)
** Zollner, G; Wagner, M; Moustafa, T; Fickert, P; Silbert, D; Gumhold, J; Fuchsbichler, A; Halilbasic, E; Denk, H; Marschall, HU; Trauner, M
Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G923-G932
Doi: 10.1152/ajpgi.00490.2005
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2005
Originalarbeit (Zeitschrift)
** Wagner, M; Halilbasic, E; Marschall, HU; Zollner, G; Fickert, P; Langner, C; Zatloukal, K; Denk, H; Trauner, M
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Hepatology. 2005; 42(2):420-430
Doi: 10.1002/hep.20784
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2004
Abstract (Zeitschrift)
** Wagner, M; Halilbasic, E; Fickert, P; Zollner, G; Fuchsbichler, A; Gumhold, J; Silbert, D; Zatloukal, K; Denk, H; Trauner, M
Nuclear receptor (PXR, CAR) agonists induce adaptive hepatic transporter and enzyme expression in mouse liver
J HEPATOL. 2004; 40: 25-25.-39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver; APR 14-18, 2004; Berlin, GERMANY.
Doi: 10.1016/S0168-8278(04)90069-4
Web of Science
FullText
FullText_MUG
** Wagner, M; Halilbasic, E; Zollner, G; Fickert, P; Gumhold, J; Silbert, D; Fuchsbichler, A; Zatloukal, K; Denk, H; Trauner, M
Xenobiotic nuclear receptor (PXR, CAR) agonists coordinately stimulate a spectrum of detoxification enzymes and transport systems involved in the adaptive response to cholestasis in vivo.
HEPATOLOGY. 2004; 40: 489A-489A.-55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD); OCT 29-NOV 02, 2004; Boston, MA.
Web of Science
** Zollner, G; Halilbasic, E; Wagner, M; Fickert, P; Silbert, D; Gumhold, J; Fuchsbichler, A; Zatloukal, K; Denk, H; Trauner, M
Cholic acid (CA) and ursodeoxycholic acid (UDCA) exert different effects on hepatic and renal expression of Mrp4 and Mrp6, two novel ABC transporters
GASTROENTEROLOGY. 2004; 126: A16-A16.
Web of Science
** Zollner, G; Halilbasic, E; Wagner, M; Fickert, P; Silbert, D; Gumhold, J; Fuchsbichler, A; Zatloukal, K; Denk, H; Trauner, M
Differential effects of ursodeoxycholic acid (UDCA) and cholic acid (CA) on hepatic and renal expression of MRP4 and MRP6, two novel abc transporters, in mice
J HEPATOL. 2004; 40: 25-25.
Doi: 10.1016/S0168-8278(04)90070-0
Web of Science
FullText
FullText_MUG